Pluristem Therapeutics (PSTI) : Tenor Capital Management has sold out all of its stake in Pluristem Therapeutics during the most recent quarter, according to the disclosure filed by the company on May 13, 2016 with the SEC. The investment management company has sold out 90,509 shares of Pluristem Therapeutics which is valued at $143,004.
Other Hedge Funds, Including , Citadel Advisors added PSTI to its portfolio by purchasing 20,772 company shares during the most recent quarter which is valued at $32,820.Group One Trading boosted its stake in PSTI in the latest quarter, The investment management firm added 14,538 additional shares and now holds a total of 28,002 shares of Pluristem Therapeutics which is valued at $44,243.Penserra Capital Management boosted its stake in PSTI in the latest quarter, The investment management firm added 4,424 additional shares and now holds a total of 13,802 shares of Pluristem Therapeutics which is valued at $21,807.
Pluristem Therapeutics (PSTI) witnessed a volatile trading activity on Wednesday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.58 and reached the intraday high at $1.59. The bulls started the profit booking and pushed the shares to intraday low of $1.57. The trading session was marked by a volume range of 35,575 shares exchanging hands. The 52-week high of the shares is $2.86 and the 52-week low is $0.71. The market cap of the company stands at $127 M and there are 8,01,61,613 shares in public circulation.
Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular orthopedic pulmonary hematological and women’s health diseases. The Company is focused on the research development clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s placenta expanded (PLX) cells are intended to function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals that are generated by the patient’s own body. PLX cells are grown using its three-dimensional (3D) micro environment technology which produces a product that requires no tissue matching prior to administration. Its PLX products are in clinical-stage development for multiple indications.